--- title: "Pharmesis International Ltd. (BFK.SG)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/BFK.SG.md" symbol: "BFK.SG" name: "Pharmesis International Ltd." industry: "Pharmaceuticals" datetime: "2026-04-14T22:04:41.472Z" locales: - [en](https://longbridge.com/en/quote/BFK.SG.md) - [zh-CN](https://longbridge.com/zh-CN/quote/BFK.SG.md) - [zh-HK](https://longbridge.com/zh-HK/quote/BFK.SG.md) --- # Pharmesis International Ltd. (BFK.SG) ## Company Overview Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | SG Market | | Website | [www.pharmesis.com](https://www.pharmesis.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-04-14T04:30:15.000Z **Overall: D (0.69)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 6 / 6 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -36.71% | | | Net Profit YoY | -150.84% | | | P/B Ratio | 1.10 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 11252351.08 | | | Revenue | 7950944.81 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -7.34% | D | | Profit Margin | -9.83% | D | | Gross Margin | 36.20% | C | | Revenue YoY | -36.71% | E | | Net Profit YoY | -150.84% | E | | Total Assets YoY | -18.60% | E | | Net Assets YoY | -11.14% | E | | Cash Flow Margin | -45.76% | E | | OCF YoY | -36.71% | E | | Turnover | 0.41 | C | | Gearing Ratio | 41.98% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Pharmesis International Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-36.71%", "rating": "" }, { "name": "Net Profit YoY", "value": "-150.84%", "rating": "" }, { "name": "P/B Ratio", "value": "1.10", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "11252351.08", "rating": "" }, { "name": "Revenue", "value": "7950944.81", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-7.34%", "rating": "D" }, { "name": "Profit Margin", "value": "-9.83%", "rating": "D" }, { "name": "Gross Margin", "value": "36.20%", "rating": "C" }, { "name": "Revenue YoY", "value": "-36.71%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-150.84%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-18.60%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-11.14%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "-45.76%", "rating": "E" }, { "name": "OCF YoY", "value": "-36.71%", "rating": "E" }, { "name": "Turnover", "value": "0.41", "rating": "C" }, { "name": "Gearing Ratio", "value": "41.98%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -14.40 | 5/6 | 9.59 | 7.59 | 6.34 | | PB | 1.10 | 2/6 | 1.35 | 1.22 | 1.10 | | PS (TTM) | 1.42 | 2/6 | 1.22 | 1.10 | 0.93 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | CMS (8A8.SG) | B | C | C | A | C | B | | 02 | Haw Par (H02.SG) | B | D | E | A | D | C | | 03 | TJ DaRenTang USD (T14.SG) | A | D | C | C | D | C | | 04 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C | | 05 | IX Biopharma (42C.SG) | E | B | C | D | C | D | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BFK.SG/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BFK.SG/norm.md) - [Related News](https://longbridge.com/en/quote/BFK.SG/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**